Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/07/17 03:07:33」(JST)

wiki en

Visilizumab (tentative trade name Nuvion, PDL BioPharma Inc.) is a humanized monoclonal antibody. It is being investigated for use as an immunosuppressive drug in patients with ulcerative colitis and Crohn's disease. Visilizumab binds to the CD3 receptor on certain activated T cells without affecting resting T cells. It is currently under clinical studies for the treatment of ulcerative colitis and Crohn's disease.^[1]

PDL BioPharma, Inc. canceled production of visilizumab following its Phase II/III clinical trials, citing its inefficacy and poor safety profile compared to other drugs on the market as the major reasons.^[2] Nevertheless, clinical trials continue for various diseases like multiple myeloma^[3] and diabetes mellitus type 1^[4]^[5] as of July 2009^[update].

Visilizumab has also been radiolabelled with technetium-99m for imaging T cells.^[6]

References

^ "PDL BioPharma, Development Pipeline - Nuvion (visilizumab)". Archived from the original on 2007-09-15. Retrieved 2008-02-11.
^ "PDL Lands in a Hazard". Retrieved 2009-05-27.
^ "Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma". ClinicalTrials.gov. Retrieved 2010-03-15.
^ Kaufman, A; Herold, KC (2009). "Anti-CD3 mAbs for treatment of type 1 diabetes". Diabetes/metabolism research and reviews 25 (4): 302–6. doi:10.1002/dmrr.933. PMID 19319985.
^ "Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes". ClinicalTrials.gov.
^ Malviya, G; D'alessandria, C; Bonanno, E; Vexler, V; Massari, R; Trotta, C; Scopinaro, F; Dierckx, R; Signore, A (2009). "Radiolabeled Humanized Anti-CD3 Monoclonal Antibody Visilizumab for Imaging Human T-Lymphocytes". Journal of Nuclear Medicine 50 (10): 1683–91. doi:10.2967/jnumed.108.059485. PMID 19759100.

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. クローン病の内科的マネージメントにおける試験研究治療 investigational therapies in the medical management of crohn disease

English Journal

Visilizumab with tacrolimus and methotrexate for GvHD prevention after allogeneic hematopoietic cell transplantation from mismatched unrelated donors.

Perez LE1,2, Fernandez H1,2, Ayala E1,2, Beato F1, Neuger A3, Pidala J1,2, Schell MJ4, Anasetti C1,2.
Bone marrow transplantation.Bone Marrow Transplant.2016 Dec 19. doi: 10.1038/bmt.2016.330. [Epub ahead of print]
PMID 27991896

Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside.

Kuhn C1, Weiner HL1.
Immunotherapy.Immunotherapy.2016 Jul;8(8):889-906. doi: 10.2217/imt-2016-0049. Epub 2016 May 10.
The induction of tolerance is a major goal of immunotherapy. Investigations over the last 20 years have shown that anti-CD3 monoclonal antibodies (mAbs) effectively treat autoimmune disease in animal models and have also shown promise in clinical trials. Tolerance induction by anti-CD3 mAbs is relat
PMID 27161438

Heterogeneous CD3 expression levels in differing T cell subsets correlate with the in vivo anti-CD3-mediated T cell modulation.

Valle A1, Barbagiovanni G1, Jofra T2, Stabilini A2, Perol L3, Baeyens A4, Anand S5, Cagnard N6, Gagliani N2, Piaggio E7, Battaglia M8.
Journal of immunology (Baltimore, Md. : 1950).J Immunol.2015 Mar 1;194(5):2117-27. doi: 10.4049/jimmunol.1401551. Epub 2015 Feb 2.
The tolerogenic anti-CD3ε monoclonal Abs (anti-CD3) are promising compounds for the treatment of type 1 diabetes. Anti-CD3 administration induces transient T cell depletion both in preclinical and in clinical studies. Notably, the said depletion mainly affects CD4(+) but not CD8(+) T cells. Moreove
PMID 25646305